Showing results (131-140 of 214) with videos related to

Sort By:
Pageof 22
Biorxiv : the Preprint Server for Biology|June 22, 2026
Antigen Stimulation Reactivates HIV-1 Proviruses Despite Integration in Repressive ChromatinAngelica Camilo-Contreras, Filippo Dragoni, Hao Zhang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 23, 2014
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsMatthew P Morrow, Pablo Tebas, Jian Yan, et al.
The Journal of Infectious Diseases|March 11, 2015
Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected WomenVincent Lo Re, Kenneth Lynn, Emily R Stumm, et al.
AIDS (London, England)|April 18, 2023
Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected personsPablo Tebas, Kenn Lynn, Livio Azzoni, et al.
The Journal of Infectious Diseases|October 6, 2005
Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 diseaseRobert C Kalayjian, John Spritzler, Minya Pu, et al.
Lancet (London, England)|September 5, 2017
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trialJoel Gallant, Adriano Lazzarin, Anthony Mills, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 26, 2020
Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1Lynn N Bertagnolli, Joseph Varriale, Sarah Sweet, et al.
Immunity|March 23, 2022
Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clonesJack A Collora, Runxia Liu, Delia Pinto-Santini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 30, 2019
NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed SubjectsEmmanouil Papasavvas, Livio Azzoni, Andrew V Kossenkov, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
Pageof 22